Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
about
Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathiesCardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population.Role of Imaging Techniques for Diagnosis, Prognosis and Management of Heart Failure Patients: Cardiac Magnetic Resonance.Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosisRecent advances in hypertrophic cardiomyopathyRole of cardiac MRI in the assessment of nonischemic cardiomyopathiesPrognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis.Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy.Role of Cardiac MR Imaging in CardiomyopathiesLate gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis.Advances in parametric mapping with CMR imaging2014 korean guidelines for appropriate utilization of cardiovascular magnetic resonance imaging: a joint report of the korean society of cardiology and the korean society of radiology.Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?Left ventricular hypertrophy: The relationship between the electrocardiogram and cardiovascular magnetic resonance imaging.Comparative study of CMR characteristics between arrhythmogenic right ventricular cardiomyopathy patients with/without syncope.Differences in apical and non-apical types of hypertrophic cardiomyopathy: a prospective analysis of clinical, echocardiographic, and cardiac magnetic resonance findings and outcome from 350 patients.Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.Characteristics of myocardial postsystolic shortening in patients with symptomatic hypertrophic obstructive cardiomyopathy before and half a year after alcohol septal ablation assessed by speckle tracking echocardiographySubclinical Myocardial Disease in Heart Failure Detected by CMR.Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion studyQuantifying late gadolinium enhancement on CMR provides additional prognostic information in early risk-stratification of nonischemic cardiomyopathy: a cohort study.High-resolution 3-dimensional late gadolinium enhancement scar imaging in surgically corrected Tetralogy of Fallot: clinical feasibility of volumetric quantification and visualization.ECG characteristics according to the presence of late gadolinium enhancement on cardiac MRI in hypertrophic cardiomyopathyProbing dynamic myocardial microstructure with cardiac magnetic resonance diffusion tensor imaging.Assessment of left ventricular twist mechanics by speckle tracking echocardiography reveals association between LV twist and myocardial fibrosis in patients with hypertrophic cardiomyopathy.Cardiac imaging in evaluating patients prone to sudden deathCoronary microvascular dysfunction: an updateHypertrophic cardiomyopathy: a reviewMyocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance studyLeft Atrial Mechanical Function and Global Strain in Hypertrophic Cardiomyopathy.Relationship between Regional Fat Distribution and Hypertrophic Cardiomyopathy PhenotypeRegional Stress-Induced Ischemia in Non-fibrotic Hypertrophied Myocardium in Young HCM Patients.Contrast-free detection of myocardial fibrosis in hypertrophic cardiomyopathy patients with diffusion-weighted cardiovascular magnetic resonance.Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunctionLate gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?European Cardiovascular Magnetic Resonance (EuroCMR) registry--multi national results from 57 centers in 15 countries.Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments.The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy.Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.
P2860
Q26765173-E32C7A31-D762-4D09-95F3-16003093261BQ26767019-100145A7-1995-41A7-8768-7F294580B7CAQ26829719-CA93763F-891B-4AFA-A84F-B9962D3B1F9CQ26864740-7C8A8FD8-5C44-4E73-AE32-32E4577C956DQ26998648-54BDD227-F885-4B91-AF96-F15DF9CC3941Q26998997-43CFBB39-ECE5-448A-A5CC-85CBB550951BQ30276294-E0A52427-C28B-4C46-9168-ABD54DAC716DQ30278822-E0F5C2B8-2269-4D9E-8BCF-559104CBF809Q30279246-A4FB412C-4534-4C3D-9DBA-DE233AD4B33BQ30407667-49FAF175-27D7-4E49-A980-248B68D4DC53Q30412201-E06B341C-6D4B-4B54-809C-609589452799Q30423759-56E09E39-0125-4D4B-9A64-3AB4E845FD86Q30430827-F2171B0C-75EC-42E8-96EA-4CA3F619ABAFQ30867239-42E02805-6414-4154-B2A9-3795F88B5443Q33164517-440EA16A-7739-4790-BE37-21350B74B5F3Q33166085-F1FEE157-D51E-4ECA-A8D7-0196D329EE74Q33168755-55A92045-1457-462F-B7C0-81C6A5C63379Q33748492-3D19E05C-5C98-4B77-8CDF-DB4A383DAC67Q34040150-8F35E9F0-8408-4D31-A5B7-91C57E1D5C66Q34091933-24037AB4-3273-48D1-BABE-4D4E8886C869Q34130016-330AD7B5-A35B-49E0-85C9-8A78D3E8C929Q34271246-84BFF829-44C4-493B-8A81-D551069018F4Q34304394-A969B82B-9A02-49BB-8C10-B6C1DF73F244Q34499443-E17E3598-3FB5-457B-98FC-0295F9880EE9Q34515672-F9FD9B4E-9005-413C-8DFF-4DDA4DF6FBA6Q34541844-3B4FB457-C0AC-468A-BA66-AA000F34F1B6Q34658569-5F8561FB-7BA4-42F5-B357-CDFB8234C134Q35024040-8BA575AF-8E43-4121-BB06-65944DFDC2D5Q35576188-DF6A615F-751E-46A5-BB2A-2E4CC6A20A87Q36059907-302E2F4B-690B-43BB-B4FD-D0BA9BE99389Q36070076-13830F1C-752E-4915-81B5-524F145B23B5Q36305091-F2D07A24-3DBE-4650-8608-9F822B9AAA2EQ36344169-1C721BB9-05B7-4855-B12D-6611775FDBD9Q36412765-7B067818-1C5E-4624-9BCF-93856DD3646EQ36571308-0A3D990E-102F-46B6-99AB-793D88CABCAAQ36588448-A4C56EEB-87F5-4E04-87E1-C3FB06220988Q37100862-7E26F556-29E3-4806-84BF-B867586EEC78Q37363558-9D387A07-9187-4583-865F-C7560950C079Q37596065-79EC697C-F05C-46D8-9664-ABD13FFA2E05Q37603719-52B64F43-6786-4B8F-8074-1E1C339C4ECC
P2860
Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@ast
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@en
type
label
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@ast
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@en
prefLabel
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@ast
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@en
P1476
Prognostic value of late gadol ...... r hypertrophic cardiomyopathy.
@en
P2093
Jeffery S Berger
John J Green
P304
P356
10.1016/J.JCMG.2011.11.021
P577
2012-04-01T00:00:00Z